Denton John Russel
See Remarks
SaleAlert
- Shares
- 7,500
- Price
- $31.82
- Value
- $238,626
SEC EDGAR · Forms 3/4/5Updated through Oct 30, 2026•40 filings
CAI
Caris Life Sciences, Inc.
Net sales of $12.4M over the last 3 months
2 sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
How to read this signal
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
−$12,370,706
0 buyers · 2 sellers
12-month purchases
$1,601,839
4 distinct insiders
12-month sales
$14,025,167
3 distinct insiders
Highlighted alerts
6
2 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get CAI insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
CAI overview: breakout setup, X sentiment and insiders in one page →
Form 4 raw → Raspberry
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
59
Raw transactions
Everything returned by the filing
8
Voluntary view
P/S trades after deterministic checks
51
Administrative noise
Stored, never alerted
6
10b5-1
Shown as informational
SEC ownership XML facts
- Code
- S
- Shares
- 119,212
- Price
- $24.76
- Footnotes
- 6
The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Exercise of stock options before their expiration date. The stock option is fully vested and exercisable.
Raspberry interpretation
Informational — no alert
Reason: tax_withholding. The filing footnotes identify tax withholding.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.
Brille Brian J
See Remarks
SaleAlert
- Shares
- 400,000
- Price
- $30.33
- Value
- $12,132,080
HALBERT JON
Director
PurchaseAlert
- Shares
- 68,000
- Price
- $14.56
- Value
- $990,080
Vacirca Jeff L
Director
PurchaseAlert
- Shares
- 31,050
- Price
- $16.15
- Value
- $501,426
Power Luke Thomas
See Remarks
Sale 10b5-1
- Shares
- 1,400
- Price
- $27.16
- Value
- $38,018
Power Luke Thomas
See Remarks
Sale 10b5-1
- Shares
- 60,850
- Price
- $26.56
- Value
- $1,616,444
Spetzler David Baxley
President
PurchaseAlert
- Shares
- 400
- Price
- $23.85
- Value
- $9,540
Denton John Russel
See Remarks
PurchaseAlert
- Shares
- 4,184
- Price
- $24.09
- Value
- $100,793
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Denton John Russel See Remarks | Sale | 7,500 | $31.82 | $238,626 | |
| Sep 17, 2026 | Brille Brian J See Remarks | Sale | 400,000 | $30.33 | $12,132,080 | |
| May 15, 2026 | HALBERT JON Director | Purchase | 68,000 | $14.56 | $990,080 | |
| May 11, 2026 | Vacirca Jeff L Director | Purchase | 31,050 | $16.15 | $501,426 | |
| Dec 11, 2025 | Power Luke Thomas See Remarks | Sale | 1,400 | $27.16 | $38,018 | |
| Dec 11, 2025 | Power Luke Thomas See Remarks | Sale | 60,850 | $26.56 | $1,616,444 | |
| Nov 07, 2025 | Spetzler David Baxley President | Purchase | 400 | $23.85 | $9,540 | |
| Nov 07, 2025 | Denton John Russel See Remarks | Purchase | 4,184 | $24.09 | $100,793 |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.